Scientific publications
GeNeuro’s science is based on more than 25 years of research, performed internally and in collaboration with renowned academic groups.
New data supporting a new precision medicine approach for ALS patients with GeNeuro’s GNK-301 presented at the 35th International Symposium on ALS/MND
Geneva, Switzerland, December 6, 2024 – 6:30 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were presented at the 35th International Symposium on ALS/MND, taking place in Montreal, Canada, from December 6-8, 2024. The presentation was delivered by Dr. Darshan Pandya, from National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH).
New data presented at the ECTRIMS 2024 Congress in Copenhagen shows that Temelimab rescues the neurodegenerative effects of HERV-W in an MS model
Geneva, Switzerland, September 19, 2024 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as a poster at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Congress in Copenhagen, Denmark. The presentation was delivered by Dr. Joel Gruchot from Prof. Patrick Küry’s group at the Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany, in collaboration with the Department of Neurology at the University of Bern, Switzerland, and the Institute of Pharmacology and Toxicology, University of Zürich, Switzerland.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021
https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
Temelimab for prevention of neurodegeneration: preclinical safety profile and design of the ProTEct-MS (temelimab following rituximab in RMS) study
MS Virtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
PNAS, July 23, 2019
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019
https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf